Steroid-refractory acute GvHD is a serious and life-threatening condition that can occur as a complication of donor haematopoietic stem cell transplantation (HSCT), used to treat blood cancers and ...

Other causes of death in the allo-HSCT arm included infections (22.8%) and graft-vs-host disease (GVHD, 10.5%). At 5 years, the cumulative incidence of acute grade 3-4 GVHD was 13.1%, and the ...

Moderate/severe chronic GVHD was found in a third (33.3%) of patients. Only two patients experienced a relapse or progressive disease; these patients were later offered retransplantation from an ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light.

The approval was based on data from the multicenter, prospective, single-arm MSB-GVHD001 trial (NCT02336230) of the allogeneic bone marrow-MSC therapy in 54 pediatric patients with steroid-refractory ...

MRD status before allo-HSCT is a strong prognostic factor for ... examined conditioning regimens and graft-versus-host-disease (GVHD) effects, finding no significant differences in DFS for MRD ...

MSCs are isolated from the bone marrow of healthy adult human donors and are used to treat SR-aGVHD in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).

An FDA advisory panel vote of 9-1 to recommend the approval of Mesoblast Limited’s graft versus host disease (GVHD) cell therapy was a cruel tease for the Australian company. More than four ...

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA.